Novartis AG
Crystalline forms of a triazolopyrimidine compound
Last updated:
Abstract:
Provided herein are crystalline forms of a triazolopyrimidine compound, which is useful for treating a PRC2-mediated disease or disorder.
Status:
Grant
Type:
Utility
Filling date:
19 Jun 2017
Issue date:
17 Aug 2021